|
N-methyl-4-({4-[({3-methyl(methylsulfonyl)amino]pyrazin-2-yl}methyl)amino]-5-(trifluoromethyl)pyrimidin-2-yl}amino)benzamide hydrochloride |
|---|---|
| Trade Name | |
| Orphan Indication | Malignant pleural mesothelioma |
| USA Market Approval | USA |
| USA Designation Date | 2013-07-18 00:00:00 |
| Sponsor | Verastem, Inc.;117 Kendrick Street, Suite 500;Needham, Massachusetts, 02494 |
